Severe CNS depression with duloxetine, ciprofloxacin and CYP2D6 deficiency—role and recognition of drug-drug-gene interactions
Authors:
- 17 January 2022
- journal article
- letter
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 78 (4) , 703-705
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- Clinical Relevance of a 16-Gene Pharmacogenetic Panel Test for Medication Management in a Cohort of 135 PatientsJournal of Clinical Medicine, 2021
- Physiologically‐Based Pharmacokinetic Modeling for the Prediction of CYP2D6‐Mediated Gene–Drug–Drug InteractionsCPT: Pharmacometrics & Systems Pharmacology, 2019
- Development, implementation and outcome analysis of semi‐automated alerts for metformin dose adjustment in hospitalized patients with renal impairmentPharmacoepidemiology and Drug Safety, 2016
- Comparative Performance of Two Drug Interaction Screening Programmes Analysing a Cross-Sectional Prescription Dataset of 84,625 Psychiatric InpatientsDrug Safety, 2013
- Augmentative Effects of Fluvoxamine on Duloxetine Plasma Levels in Depressed PatientsPharmacopsychiatry, 2011
- Genotype-Based Quantitative Prediction of Drug Exposure for Drugs Metabolized by CYP2D6Clinical Pharmacology & Therapeutics, 2011
- Quantitative Prediction of Cytochrome P450 (CYP) 2D6-Mediated Drug InteractionsClinical Pharmacokinetics, 2011